ERβ up-regulation was involved in silibinin-induced growth inhibition of human breast cancer MCF-7 cells. 2016

Nan Zheng, and Lu Liu, and Weiwei Liu, and Ping Zhang, and Huai Huang, and Linghe Zang, and Toshihiko Hayashi, and Shin-ichi Tashiro, and Satoshi Onodera, and Mingyu Xia, and Takashi Ikejima
China-Japan Research Institute of Medical and Pharmaceutical Sciences, Shenyang Pharmaceutical University, Shenyang 110016, China.

We previously reported that silibinin induced a loss of cell viability in breast cancer (MCF-7) cells by ERα down-regulation. But whether this cytotoxicity depends on another estrogen receptor, ERβ, has yet to be elucidated. Therefore, we sought to explore the effects of ERβ modulation on cell viability by using an ERβ-selective agonist (Diarylprepionitrile, DPN) and an antagonist (PHTPP). Our data demonstrated that ERβ served as a growth suppressor in MCF-7 cells, and the incubation of silibinin, elevated ERβ expression, resulting in the tumor growth inhibition. The cytotoxic effect of silibinin was diminished by PHTPP and enhanced by DPN. Silencing of ERβ by siRNA confirmed these results. Apoptotic cascades, including the sequential activation of caspase-9 and -6, and finally the cleavage of caspase substrates, PARP and ICAD, caused by treatment with silibinin, were all repressed by PHTPP pre-treatment but exacerbated by DPN. Unlike ERα, ERβ did not involve autophagic process in the regulation, since neither autophagic inhibitor (3-MA) nor the inducer (rapamycin) affected the cell survival rates regardless ERβ activity. Taken together, silibinin induced apoptosis through mitochondrial pathway by up-regulating ERβ pathways in MCF-7 cells without the involvement of autophagy.

UI MeSH Term Description Entries
D008928 Mitochondria Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Each mitochondrion is surrounded by a double limiting membrane. The inner membrane is highly invaginated, and its projections are called cristae. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP. They contain distinctive RIBOSOMES, transfer RNAs (RNA, TRANSFER); AMINO ACYL T RNA SYNTHETASES; and elongation and termination factors. Mitochondria depend upon genes within the nucleus of the cells in which they reside for many essential messenger RNAs (RNA, MESSENGER). Mitochondria are believed to have arisen from aerobic bacteria that established a symbiotic relationship with primitive protoeukaryotes. (King & Stansfield, A Dictionary of Genetics, 4th ed) Mitochondrial Contraction,Mitochondrion,Contraction, Mitochondrial,Contractions, Mitochondrial,Mitochondrial Contractions
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077385 Silybin The major active component of silymarin flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum; it is used in the treatment of HEPATITIS; LIVER CIRRHOSIS; and CHEMICAL AND DRUG INDUCED LIVER INJURY, and has antineoplastic activity; silybins A and B are diastereomers. 2,3-Dehydrosilybin,Alepa-forte,Ardeyhepan,Cefasilymarin,Durasilymarin,Hepa-Merz Sil,Hepa-loges,HepaBesch,Hepar-Pasc,Heparsyx,Heplant,Lagosa,Legalon Forte,Silibin,Silibinin,Silibinin A,Silibinin B,Silybin A,Silybin B,Silybinin,2,3 Dehydrosilybin,Alepa forte,Hepa Merz Sil,Hepa loges,Hepar Pasc
D012838 Silymarin A mixture of flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum. It consists primarily of silybin and its isomers, silicristin and silidianin. Silymarin displays antioxidant and membrane stabilizing activity. It protects various tissues and organs against chemical injury, and shows potential as an antihepatoxic agent. Carsil,Karsil,Legalon,Silimarin
D015854 Up-Regulation A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D047629 Estrogen Receptor beta One of the ESTROGEN RECEPTORS that has greater affinity for ISOFLAVONES than ESTROGEN RECEPTOR ALPHA does. There is great sequence homology with ER alpha in the DNA-binding domain but not in the ligand binding and hinge domains. ERbeta,ERbetacx,Estrogen Receptor 2,Estrogen Receptors beta,Receptor beta, Estrogen
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D061986 MCF-7 Cells An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.) MCF7 Cells,Michigan Cancer Foundation 7 Cells,Cell, MCF-7,Cell, MCF7,Cells, MCF-7,Cells, MCF7,MCF 7 Cells,MCF-7 Cell,MCF7 Cell

Related Publications

Nan Zheng, and Lu Liu, and Weiwei Liu, and Ping Zhang, and Huai Huang, and Linghe Zang, and Toshihiko Hayashi, and Shin-ichi Tashiro, and Satoshi Onodera, and Mingyu Xia, and Takashi Ikejima
March 2011, Journal of breast cancer,
Nan Zheng, and Lu Liu, and Weiwei Liu, and Ping Zhang, and Huai Huang, and Linghe Zang, and Toshihiko Hayashi, and Shin-ichi Tashiro, and Satoshi Onodera, and Mingyu Xia, and Takashi Ikejima
July 2000, Biochemical and biophysical research communications,
Nan Zheng, and Lu Liu, and Weiwei Liu, and Ping Zhang, and Huai Huang, and Linghe Zang, and Toshihiko Hayashi, and Shin-ichi Tashiro, and Satoshi Onodera, and Mingyu Xia, and Takashi Ikejima
January 2010, Free radical research,
Nan Zheng, and Lu Liu, and Weiwei Liu, and Ping Zhang, and Huai Huang, and Linghe Zang, and Toshihiko Hayashi, and Shin-ichi Tashiro, and Satoshi Onodera, and Mingyu Xia, and Takashi Ikejima
December 1991, Nihon Sanka Fujinka Gakkai zasshi,
Nan Zheng, and Lu Liu, and Weiwei Liu, and Ping Zhang, and Huai Huang, and Linghe Zang, and Toshihiko Hayashi, and Shin-ichi Tashiro, and Satoshi Onodera, and Mingyu Xia, and Takashi Ikejima
May 2010, Free radical research,
Nan Zheng, and Lu Liu, and Weiwei Liu, and Ping Zhang, and Huai Huang, and Linghe Zang, and Toshihiko Hayashi, and Shin-ichi Tashiro, and Satoshi Onodera, and Mingyu Xia, and Takashi Ikejima
March 2016, Journal of breast cancer,
Nan Zheng, and Lu Liu, and Weiwei Liu, and Ping Zhang, and Huai Huang, and Linghe Zang, and Toshihiko Hayashi, and Shin-ichi Tashiro, and Satoshi Onodera, and Mingyu Xia, and Takashi Ikejima
July 2008, Journal of pharmacological sciences,
Nan Zheng, and Lu Liu, and Weiwei Liu, and Ping Zhang, and Huai Huang, and Linghe Zang, and Toshihiko Hayashi, and Shin-ichi Tashiro, and Satoshi Onodera, and Mingyu Xia, and Takashi Ikejima
January 2005, Molecular cancer therapeutics,
Nan Zheng, and Lu Liu, and Weiwei Liu, and Ping Zhang, and Huai Huang, and Linghe Zang, and Toshihiko Hayashi, and Shin-ichi Tashiro, and Satoshi Onodera, and Mingyu Xia, and Takashi Ikejima
June 2002, Cancer research and treatment,
Nan Zheng, and Lu Liu, and Weiwei Liu, and Ping Zhang, and Huai Huang, and Linghe Zang, and Toshihiko Hayashi, and Shin-ichi Tashiro, and Satoshi Onodera, and Mingyu Xia, and Takashi Ikejima
July 1995, Cancer letters,
Copied contents to your clipboard!